178
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Antitumor potential of tricyclic pyridone analogues from an entomopathogenic fungus, Fusarium avenaceum SYKC02-P-1

&
Pages 139-146 | Received 01 Mar 2022, Accepted 27 Apr 2022, Published online: 11 May 2022
 

Abstract

Two new tricyclic pyridone analogues, fusapyridons C (1) and D (2), were isolated along with structurally related known compounds 3  5 from the entomopathogenic fungus, F. avenaceum SYKC02-P-1. The structures of compounds 1 and 2 were elucidated by analyzing the spectral data of UV, 1 D and 2 D NMR as well as HRESIMS. The absolute configurations of fusapyridons C and D were established by means of single crystal X-ray diffraction and electronic circular dichroism calculation. And antitumor testing of all the isolates showed that compounds 4 and 5 exhibited significant inhibitory activity against the human prostate cancer cells (PC-3 cell lines) with IC50 values of 2.76 and 1.86 μM, respectively.

Graphical Abstract

Acknowledgements

We are grateful to Mr. Jian Hao from the Department of Analytical Testing Center, Beijing University of Chemical Technology, for the test of X-ray diffraction.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.